RAP - The Main Game, page-528

Some good discussion and debate here...it's been awhile, let's admit.

Regarding costs vs benefits of ResAppDx vs Stethoscope...here are some back of the envelope numbers:

- Google says there are 3M pneumonia patients in the US each year (adults + kids).

Let's assume:
- ResApp Dx ~90% accuracy…ie. ~10% false positive patients go for x-ray
- Stethoscope only ~65% accuracy…ie ~35% false positive patients go for x-ray

- So ~25% additional patients sent for chest x-ray using stethoscope vs ResApp Dx

Cost of false positive x-rays = 750,000 patients x $200/test = $150M

Reasonable conclusion??? pneumonia diagnosis market alone is big and there are sufficient incentives on a cost basis for hospitals, GP's and telehealth providers to utilise the technology once it is approved. Note the total respiratory market (including diagnosis and management of Asthma, bronchiolitis, croup, COPD etc) is more than two orders of magnitude bigger (ie. 3M pneumonia patients vs 125M respiratory visits in the USA)

RAP has the potential to be a very, very big deal.

GLTA